


Objective, Standardized Biopsy Analysis Using mRNA Profiling

The Molecular Microscope® Diagnostic System (MMDx) is the future of transplant management. Using microarray technology to analyze mRNA expression, this biopsy service detects injury or rejection for a transplanted organ at the molecular level. MMDx provides a standardized and objective assessment that allows clinicians to rapidly target treatment to a patient's individual needs.

Agreement Between Pathologists in Biopsy Diagnosis

TCMR diagnosis
concordance between pathologists
by type of transplant:

Histopathology scores are currently the primary tool for diagnosing injury or rejection; however studies show that pathologists often disagree when it comes to TCMR diagnosis. Additionally, the quality of the biopsy samples can sometimes affect histology results, rendering the samples unreadable.



Advantages of MMDx

- **Minimally invasive:** Requires less tissue than histology (5 mm for kidney and liver, 2 bites for heart and lung)
- **Convenient:** Simply put biopsied tissue into a prepared tube (containing RNAlater®) at room temperature
- **Fast turnaround:** Results available 1-2 business days from receipt of sample
- **Actionable data:** Provides objective, quantitative, probabilistic risk assessment

References

1. Reeve, J. et al. (2013). Molecular Diagnosis of T Cell-Mediated Rejection in Human Kidney Transplant Biopsies. *American Journal of Transplantation*, 13(3), 645-655.
2. Crespo-Leiro, M.G. et al. (2012). Concordance Among Pathologists in the Second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II). *Transplantation*, 94(11), 1172-1177.
3. Arcasoy, S.M. (2011). Pathologic Interpretation of Transbronchial Biopsy for Acute Rejection of Lung Allograft is Highly Variable. *American Journal of Transplantation*, 11(2), 320-328.

Contact Us

1lambda-mmdx@thermofisher.com

molecular-Microscope.com

DISCLAIMERS:

Molecular Microscope is a registered trademark of Transcriptome Sciences Inc. MMDx was developed by Transcriptome Sciences Inc. MMDx testing services are performed by authorized laboratories under a sublicense from One Lambda, Inc., a part of Thermo Fisher Scientific. Authorized testing laboratories in the US are certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.